Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.
Fautrel B, Bouhnik Y, Salliot C, Carbonnel F, Fumery M, Bernardeau C, Maugars Y, Flamant M, Coury F, Braithwaite B, Hateb S, Addison J; PERFUSE investigators. Fautrel B, et al. Among authors: addison j. Drugs Real World Outcomes. 2025 Jan 16. doi: 10.1007/s40801-024-00477-4. Online ahead of print. Drugs Real World Outcomes. 2025. PMID: 39821191 No abstract available.
Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.
Fautrel B, Bouhnik Y, Salliot C, Carbonnel F, Fumery M, Bernardeau C, Maugars Y, Flamant M, Coury F, Braithwaite B, Hateb S, Addison J; PERFUSE investigators. Fautrel B, et al. Among authors: addison j. Drugs Real World Outcomes. 2024 Dec;11(4):573-591. doi: 10.1007/s40801-024-00459-6. Epub 2024 Oct 10. Drugs Real World Outcomes. 2024. PMID: 39384685 Free PMC article.
Collective knowledge exchange through regional hubs: Local expertise, global platform.
Llamas CA, Guinto R, Addison J, Alam N, Amoakoh HB, Artola Arita V, Kolpa N, Mattijsen J, Zhang Y, Downward GS, Browne JL. Llamas CA, et al. Among authors: addison j. Trop Med Int Health. 2024 Oct;29(10):849-855. doi: 10.1111/tmi.14041. Epub 2024 Sep 10. Trop Med Int Health. 2024. PMID: 39253880 No abstract available.
A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48).
Leng X, Leszczyński P, Jeka S, Liu S, Liu H, Miakisz M, Gu J, Kilasonia L, Stanislavchuk M, Yang X, Zhou Y, Dong Q, Mitroiu M, Addison J, Rezk MF, Zeng X. Leng X, et al. Among authors: addison j. Arthritis Res Ther. 2024 Sep 7;26(1):157. doi: 10.1186/s13075-024-03375-w. Arthritis Res Ther. 2024. PMID: 39244595 Free PMC article. Clinical Trial.
220 results